Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
288 participants
OBSERVATIONAL
1999-07-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Pharmacovigilance Of Refacto AF
NCT00895037
Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
NCT00092976
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
NCT00884390
Study Evaluating ReFacto in Hemophilia A
NCT00038909
Study Evaluating ReFacto AF in Severe Hemophilia A
NCT00037544
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients with Hemophilia A
Moroctocog alfa
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moroctocog alfa
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Vienna, Vienna, Austria
Pfizer Investigational Site
Berlin, Germany, Germany
Pfizer Investigational Site
Wiesbaden, Germany, Germany
Pfizer Investigational Site
Frankfurt am Main, Hesse, Germany
Pfizer Investigational Site
Giessen, Hesse, Germany
Pfizer Investigational Site
Hanover, Lower Saxony, Germany
Pfizer Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany
Pfizer Investigational Site
Bonn, North Rhine-Westphalia, Germany
Pfizer Investigational Site
Halle, Saxony-Anhalt, Germany
Pfizer Investigational Site
Stadtroda, Thuringia, Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bermen, , Germany
Pfizer Investigational Site
Erlangen, , Germany
Pfizer Investigational Site
Frankfurt A. M., , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Heidelberg, , Germany
Pfizer Investigational Site
Homburg, , Germany
Pfizer Investigational Site
Klipphausen, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Lübeck, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Potsdam, , Germany
Pfizer Investigational Site
Schwerin, , Germany
Pfizer Investigational Site
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3082A-100690
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.